Moderna (MRNA) shares plummeted 25% despite generally positive data on a personalized anti-cancer vaccine. The drug reduced the risk of melanoma recurrence or death in a subset of patients by 42% — however, the market had expected significantly more impressive results.

Some of the clinical data became publicly available before the company's official release, which amplified volatility in the stock. Notably, even after such a sharp correction, Moderna's share price gain since the start of 2026 exceeds 530% — investors are still pricing in significant potential for the oncology segment.

What the vaccine showed

For comparison: shares of Merck — a significantly larger pharmaceutical corporation — fell by roughly 1%, while gaining almost 41% since the start of the year. Such a contrasting reaction underscores just how high expectations were specifically for Moderna.

The focus is on intismeran autogene — a personalized vaccine targeting mutations in an individual patient's tumor. It is used in combination with Keytruda, Merck's immunotherapy drug. After two years, approximately 82% of patients receiving the combination remained recurrence-free, versus 70% among those receiving Keytruda alone. The combination reduced the risk of distant metastasis or death by 38%.

Is this enough for further growth

The trial was conducted on only one tumor type. Merck's leadership acknowledges that more data will be needed to prove the vaccine's efficacy against other cancer types. The company is currently conducting studies in lung, bladder, and skin cancers — success in these areas would allow Moderna to bring a commercial product to market outside its Covid-19, flu, and RSV vaccine lines.

The main challenge is manufacturing: a personalized dose is created in six weeks and depends on tumor sequencing. Merck claims it can reduce this time so patients receive the vaccine faster. Full Phase 3 results will be presented at the European Society for Medical Oncology (ESMO) conference this weekend — and they will determine the stock's further trajectory.

Cryptalist analysis: The sharp market reaction reflects not doubts about the drug's efficacy, but the scale of inflated expectations baked into the price after a 530% gain since the start of the year. For institutional investors, the key trigger will be the full ESMO data: confirmation of the effect in other tumor types could restart the rally, while disappointment risks deepening the correction.